Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 9/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.34 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | GANAB | Q14697 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24635571 | 1.00 | SLC18A3 (0.56) | SLC18A3HTR6GAACYP1A2CYP2C9 | |
| SCHEMBL24635570 | 1.00 | SLC18A3 (0.56) | SLC18A3HTR6GAACYP1A2CYP2C9 | |
| SCHEMBL10181569 | 1.00 | SLC18A3 (0.56) | SLC18A3HTR6GAACYP1A2CYP2C9 | |
| SCHEMBL2203407 | 0.83 | SLC18A3 (0.57) | SLC18A3HTR6 | |
| SCHEMBL2203410 | 0.83 | SLC18A3 (0.57) | SLC18A3HTR6 | |
| SCHEMBL2203412 | 0.83 | SLC18A3 (0.57) | SLC18A3HTR6 | |
| SCHEMBL3099483 | 0.82 | SLC18A3 (0.44) | SLC18A3GAAGBA2GBA1 | |
| Hydrochloric Acid SCHEMBL2201100 | 0.81 | SLC18A3 (0.55) | SLC18A3HTR6TSHRSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2201095 | 0.81 | SLC18A3 (0.55) | SLC18A3HTR6TSHRSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2201097 | 0.81 | SLC18A3 (0.55) | SLC18A3HTR6TSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115590854-B | Pyridazinyl thiazole carboxamides | 安斯泰来制药株式会社 | 2024-06-07 | — | — | CN | disclosed |
| US-8097618-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097618-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2336136-A1 | Pyridine derivatives and their use in the treatment of psychotic disorders | GlaxoSmithKline LLC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7919491-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919491-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| CN-101305011-B | Pyridine derivatives and their use in the treatment of psychotic disorders | SMITHKLINE BEECHAM CORP | 2011-03-02 | — | — | CN | disclosed |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| CN-101305011-A | Pyridine derivatives and their use in the treatment of psychotic disorders | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | CN | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| EP-1928886-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SmithKline Beecham Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | NDUFB7, NDUFB6, GABRE | SLC18A3 349/4885HTR6 159/4885GAA 826/4885 |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | SLC6A3, NDUFS5, NDUFB6 | SLC18A3 370/4885HTR6 182/4885GAA 1165/4885 |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | CHRNA7, NR3C2, CHRNA6 | SLC18A3 565/4885HTR6 100/4885GAA 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.